Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Florence – page 11

820 clinical trials in Florence, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Florence at a glance
820
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

820 trials in Florence

Open in trial search

A Study of Maribavir for Cytomegalovirus Infection in Stem Cell Transplant Patients Who Cannot Take or Did Not Tolerate Standard Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Maribavir
  • Sponsor:Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare

Cardiac failure

Recruiting

A Study Testing Drug Combination for Heart Failure in Women Comparing Increased Doses to Standard Care

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol
  • Sponsor:Policlinico San Donato S.p.A.

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD8205
  • Sponsor:AstraZeneca AB

A study testing intranasal esketamine compared to midazolam for rapidly reducing symptoms of major depressive disorder in adolescents with suicidal thoughts or behavior

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Esketamine
  • Sponsor:Janssen Cilag International

A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Imbria Pharmaceuticals Inc.

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AB521
  • Sponsor:Arcus Biosciences Inc.

A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:Relay Therapeutics Inc.

A study testing DFL24498 eye drop solution to improve eye itching in adults with atopic keratoconjunctivitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S,34R)-30-Ethyl-34-[(E,2R)-Hex-4-En-2-Yl]-4,7,10,12,15,19,25,28-Octamethyl-33-(Methylamino)-6,9,18,24-Tetrakis(2-Methylpropyl)-3,21-Di(Propan-2-Yl)-1-Oxa-4,7,10,13,16,19,22,25,28,31-Decazacyclotetratriacontane-2,5,8,11,14,17,20,23,26,29,32-Undecone Hydrochloride
  • Sponsor:Dompe' Farmaceutici S.p.A.

Hidradenitis

Recruiting

A Study of LAD191 Compared to Placebo and Adalimumab in Adults with Moderate-to-Severe Hidradenitis Suppurativa

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Almirall S.A.

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Florence

What the registry says about research in the country

01 Neurological Disorders

Clinical research focusing on innovative treatments for frontotemporal dementia, multiple sclerosis, and Dravet syndrome. Studies evaluate novel therapeutic approaches including DNL593 for FTD and frexalimab for relapsing MS.

  • Frontotemporal Dementia Treatment
  • Multiple Sclerosis Management
  • Seizure Control in Dravet Syndrome

Emphasis on safety assessment and long-term efficacy monitoring.

02 Oncology Research

Comprehensive studies targeting various cancer types including colorectal cancer, breast cancer, and lung cancer. Trials explore combination therapies and novel treatment approaches.

  • Metastatic Colorectal Cancer Treatment
  • Advanced Breast Cancer Therapies
  • NSCLC Post-Surgery Care

Focus on targeted therapies and personalized treatment approaches.

03 Autoimmune Conditions

Investigating treatments for psoriatic arthritis, Sjögren's syndrome, and systemic sclerosis. Research includes evaluation of new biologics and targeted therapies.

  • Psoriatic Arthritis Management
  • Sjögren's Syndrome Treatment
  • Systemic Sclerosis Interventions

Studies aim to improve quality of life and disease management.

04 Respiratory Medicine

Studies examining treatments for COPD and respiratory infections, including evaluation of tezepelumab for moderate to severe COPD and prevention of RSV in infants.

  • COPD Exacerbation Management
  • RSV Prevention in Infants
  • Respiratory Disease Therapies

Focus on improving respiratory outcomes and prevention strategies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.